title: The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
abstract: OBJECTIVE
  To determine if quantification of [18F]fluorodeoxyglucose (18F-FDG) uptake in a thyroid nodule found incidentally on whole-body 18F-FDG positron emission tomography-computed tomography (PET-CT) can be used to discriminate between malignant and benign aetiology.
  
  
  METHODS
  A retrospective review of all patients with focally high uptake in the thyroid as an incidental finding on 18F-FDG PET-CT from May 2003 through May 2006. The uptake in the nodules was quantified using the maximum standardized uptake value (SUVmax). The aetiology was determined by cytology and/or ultrasound, or on histopathology.
  
  
  RESULTS
  Incidental focally high uptake was found in 79/7347 patients (1.1%). In 31/48 patients with adequate follow-up, a benign aetiology was determined. Median SUVmax for the benign group was 5.6, range 2.5-53. Malignancy was confirmed in 15/48 patients. The malignancies were papillary thyroid carcinoma in 12, metastasis from squamous cell carcinoma in one, and lymphoma in two. Median SUVmax for the malignant lesions was 6.4, range 3.5-16. Cytology suspicious for follicular carcinoma was found in 2/48 patients. No statistical difference (P=0.12) was found among the SUVmax between the benign and malignant groups.
  
  
  CONCLUSIONS
  Focally high uptake of 18F-FDG in the thyroid as an incidental finding occurred in 1.1% of the patients. Malignancy was confirmed or was suspicious in 17/48 (35%) of the patients that had adequate follow-up. There was no significant difference in the SUVmax between benign and malignant nodules.
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Trond V
authors.initials: TV
authors.lastname: Bogsrud
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Karantanis
authors.forename: Mark A
authors.initials: MA
authors.lastname: Nathan
authors.forename: Brian P
authors.initials: BP
authors.lastname: Mullan
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Wiseman
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Collins
authors.forename: Jan L
authors.initials: JL
authors.lastname: Kasperbauer
authors.forename: Scott E
authors.initials: SE
authors.lastname: Strome
authors.forename: Carl C
authors.initials: CC
authors.lastname: Reading
authors.forename: Ian D
authors.initials: ID
authors.lastname: Hay
authors.forename: Val J
authors.initials: VJ
authors.lastname: Lowe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D033162:Incidental Findings; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D016606:Thyroid Nodule / Q000175:diagnosis* / Q000378:metabolism*; D014057:Tomography, X-Ray Computed / Q000379:methods*; D051598:Whole Body Imaging / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18